MedTrace Logo

ASTERIX: Low Dose ASA and Nexium

NCT00251966 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 960

Last updated 2009-03-12

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effect of esomeprazole 20 mg od versus placebo for the prevention of gastric and/or duodenal ulcers in patients taking low-dose ASA.

Conditions

  • Gastroesophageal Reflux

Interventions

DRUG

Esomeprazole

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Nexium Medical Science Director, MD · AstraZeneca

  • Neville Yeomans, MD · Perth Medical School

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2005-09-30

Countries

  • Australia
  • Bulgaria
  • Canada
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Italy
  • South Africa
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00251966 on ClinicalTrials.gov